Literature DB >> 9087503

Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.

S K Spangler1, M R Jacobs, P C Appelbaum.   

Abstract

The activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, piperacillin, piperacillin-tazobactam, imipenem, clindamycin, and metronidazole against 11 anaerobes were tested by the broth microdilution and time-kill methods. DU-6859a was the most active drug tested (broth microdilution MICs, 0.06 to 0.5 microg/ml), followed by imipenem (MICs, 0.002 to 4.0 microg/ml). Broth macrodilution MICs were within 3 (but usually 1) dilutions of the broth microdilution MICs. All compounds were bactericidal at the MIC after 48 h; after 24 h, 90% killing was shown for all strains when the compounds were used at four times the MIC. DU-6859a at < or = 0.5 microg/ml was bactericidal after 48 h.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9087503      PMCID: PMC163808     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.

Authors:  V Korten; J F Tomayko; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

2.  In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.

Authors:  S A Marshall; R N Jones; P R Murray; J A Washington; S D Allen; E H Gerlach; M E Erwin
Journal:  J Antimicrob Chemother       Date:  1993-12       Impact factor: 5.790

3.  The in-vitro activity of a new highly active quinolone, DU-6859a.

Authors:  A Jolley; J M Andrews; N Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790

4.  MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

5.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 6.  Quinolone activity against anaerobes: microbiological aspects.

Authors:  P C Appelbaum
Journal:  Drugs       Date:  1995       Impact factor: 9.546

7.  In vitro activity of DU-6859a against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Reeves; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

8.  Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods.

Authors:  G A Pankuch; M R Jacobs; S F Rittenhouse; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  beta-Lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents.

Authors:  M R Jacobs; S K Spangler; P C Appelbaum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

10.  In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.

Authors:  S A Marshall; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

View more
  10 in total

1.  Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.

Authors:  Kim L Credito; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.

Authors:  Dianne B Hoellman; Linda M Kelly; Kim Credito; Lauren Anthony; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes.

Authors:  S L Pendland; M Diaz-Linares; K W Garey; J G Woodward; S Ryu; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.

Authors:  K L Credito; L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 5.  Quinolone activity against anaerobes.

Authors:  P C Appelbaum
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.

Authors:  L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Phytochemical investigation and anti-microbial activity of Clausena anisata (Willd), Hook.

Authors:  Nicholas Agyepong; Christian Agyare; Martin Adarkwa-Yiadom; Stephen Yao Gbedema
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-04-03

8.  In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.

Authors:  D B Hoellman; S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 9.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

10.  Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.

Authors:  Kim L Credito; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.